Stock Market News3 months SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies Zacks
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
XSarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
X